Arena Pharmaceuticals’ APD418 gets FDA fast track status in decompensated heart failure

Arena Pharmaceuticals’ APD418 gets FDA fast track status in decompensated heart failure

Arena Pharmaceuticals has secured that fast track designation for its drug candidate APD418 from the US Food and Drug Administration (FDA) for the treatment of decompensated heart failure (DHF). APD418 is a β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope. According to the San Diego-based biopharma company, APD418 is a selective antagonist that has been designed […]

Arena begins ADVISE clinical trial for etrasimod in atopic dermatitis

Arena begins ADVISE clinical trial for etrasimod in atopic dermatitis

Arena Pharmaceuticals has dosed the first subject in the phase 2 ADVISE clinical trial, which is evaluating etrasimod for the treatment of moderate-to-severe atopic dermatitis (AD). Etrasimod is a once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator. Atopic dermatitis is considered to be a serious, chronic immune-mediated disease in which symptoms are varied. However, the usual […]